ESMO 2022
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
2022-09-13
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022
2022-09-13
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
2022-09-12